CompletedPhase 3NCT01735006
Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine
Studying Vulvar intraepithelial neoplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Xiamen University
- Principal Investigator
- Jun Zhang, MasterXiamen University
- Intervention
- HPV Vaccine(biological)
- Enrollment
- 7372 target
- Eligibility
- 18-45 years · FEMALE
- Timeline
- 2012 – 2019
Study locations (1)
- Cancer Institute ＆ Hospital Chinese Academy of Medical Sciences, Beijing, China
Collaborators
Xiamen Innovax Biotech Co., Ltd · Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. · Ministry of Science and Technology of the People´s Republic of China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01735006 on ClinicalTrials.gov